These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2477071)

  • 1. CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: its relationship to severity of dementia and monoamine metabolites.
    Pomara N; Singh RR; Deptula D; LeWitt PA; Bissette G; Stanley M; Nemeroff CB
    Biol Psychiatry; 1989 Sep; 26(5):500-4. PubMed ID: 2477071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression.
    Molchan SE; Lawlor BA; Hill JL; Martinez RA; Davis CL; Mellow AM; Rubinow DR; Sunderland T
    Biol Psychiatry; 1991 Jun; 29(11):1110-8. PubMed ID: 1714776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Hydroxyindoleacetic acid and homovanillic acid concentrations in cerebrospinal fluid in patients with Alzheimer's disease, depression and mild cognitive impairment.
    Stuerenburg HJ; Ganzer S; Müller-Thomsen T
    Neuro Endocrinol Lett; 2004 Dec; 25(6):435-7. PubMed ID: 15665806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasopressin levels in CSF of Alzheimer patients: correlations with monoamine metabolites and neuropsychological test performance.
    Jolkkonen J; Helkala EL; Kutvonen R; Lehtinen M; Riekkinen PJ
    Psychoneuroendocrinology; 1989; 14(1-2):89-95. PubMed ID: 2471986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia.
    Bråne G; Gottfries CG; Blennow K; Karlsson I; Lekman A; Parnetti L; Svennerholm L; Wallin A
    Alzheimer Dis Assoc Disord; 1989; 3(3):148-56. PubMed ID: 2477044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease.
    Blennow K; Wallin A; Gottfries CG; Lekman A; Karlsson I; Skoog I; Svennerholm L
    Neurobiol Aging; 1992; 13(1):107-13. PubMed ID: 1371850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropsychological test performance and CSF levels of monoamine metabolites in healthy volunteers and patients with Alzheimer's dementia.
    Nybäck H; Nyman H; Schalling D
    Acta Psychiatr Scand; 1987 Dec; 76(6):648-56. PubMed ID: 2450445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine metabolites, corticotropin releasing factor and somatostatin as CSF markers in depressed patients.
    Widerlöv E; Bissette G; Nemeroff CB
    J Affect Disord; 1988; 14(2):99-107. PubMed ID: 2452842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.
    Morimoto S; Takao M; Hatsuta H; Nishina Y; Komiya T; Sengoku R; Nakano Y; Uchino A; Sumikura H; Saito Y; Kanemaru K; Murayama S
    PLoS One; 2017; 12(2):e0171524. PubMed ID: 28166276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF monoamine metabolites in old age dementias.
    Parnetti L; Gaiti A; Reboldi GP; Santucci C; Mecocci P; Brunetti M; Cadini D; Senin U
    Mol Chem Neuropathol; 1992; 16(1-2):143-57. PubMed ID: 1381590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia.
    Palmer AM; Sims NR; Bowen DM; Neary D; Palo J; Wikstrom J; Davison AN
    J Neurol Neurosurg Psychiatry; 1984 May; 47(5):481-4. PubMed ID: 6204017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid concentrations of biogenic amines and corticotropin-releasing factor in adolescent non-human primates as a function of the timing of adverse early rearing.
    Mathew SJ; Coplan JD; Smith EL; Scharf BA; Owens MJ; Nemeroff CB; Mann JJ; Gorman JM; Rosenblum LA
    Stress; 2002 Sep; 5(3):185-93. PubMed ID: 12186681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.
    Gibson CJ; Logue M; Growdon JH
    Arch Neurol; 1985 May; 42(5):489-92. PubMed ID: 2581531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylcholinesterase activities and monoamine metabolite levels in the cerebrospinal fluid of patients with Alzheimer's disease.
    Kawakatsu S; Morinobu S; Shinohara M; Totsuka S; Kobashi K
    Biol Psychiatry; 1990 Sep; 28(5):387-400. PubMed ID: 1698467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective attention in Alzheimer's disease: CSF correlates of behavioral impairments.
    Freed DM; Corkin S; Growdon JH; Nissen MJ
    Neuropsychologia; 1988; 26(6):895-902. PubMed ID: 2461537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease.
    Alhainen K; Helkala EL; Reinikainen K; Riekkinen P
    J Neural Transm Park Dis Dement Sect; 1993; 5(3):185-92. PubMed ID: 7690228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homovanillic acid and 5-hydroxyindoleacetic acid levels in cerebrospinal fluid of patients with senile dementia of Alzheimer type.
    Soininen H; MacDonald E; Rekonen M; Riekkinen PJ
    Acta Neurol Scand; 1981 Aug; 64(2):101-7. PubMed ID: 6172950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF beta-endorphin, HVA and 5-HIAA of dementia of the Alzheimer type and Binswanger's disease in the elderly.
    Lee S; Chiba T; Kitahama T; Kaieda R; Hagiwara M; Nagazumi A; Terashi A
    J Neural Transm Suppl; 1990; 30():45-55. PubMed ID: 1697333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease.
    Sjögren M; Minthon L; Passant U; Blennow K; Wallin A
    Neurobiol Aging; 1998; 19(5):379-84. PubMed ID: 9880039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced cerebrospinal fluid dynorphin A1-8 in Alzheimer's disease.
    Sunderland T; Berrettini WH; Molchan SE; Lawlor BA; Martinez RA; Vitiello B; Tariot PN; Cohen RM
    Biol Psychiatry; 1991 Jul; 30(1):81-7. PubMed ID: 1716470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.